VIDEO | 05:00
Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.
{{{ _highlightResult.query.value }}}
{{ category }}
{{{ _highlightResult.full_name.value }}}
{{{ _highlightResult.summary.value }}}
{{ category }}
{{{ _highlightResult.title.value }}}
{{{ _highlightResult.summary.value }}}
{{ category }}
{{{ _highlightResult.title.value }}}
{{ address.address_line_1 }}
{{ address.address_line_2 }}
{{ address.city }}
{{ address.state }}
{{ address.zip_code }}